Overview

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

Status:
RECRUITING

Trial end date:
2028-08-24

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary efficacy of BMS-986507 combinations in adult participants with advanced solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Nivolumab
osimertinib
pembrolizumab